ELTP earnings analysis
What we found in ELTP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Elite reported $40.748 million of revenue and $0.01 of EPS, but the provided filing excerpt does not disclose margin, cash-flow, balance-sheet, or segment trends. The most material disclosure is management’s conclusion that disclosure controls and internal control over financial reporting were ineffective as of June 30, 2026, due to 3 categories of material weaknesses. The Purdue Pharma litigation was dismissed on June 12, 2026, but generic OxyContin commercialization remains contingent on FDA approval and patent outcomes. No quantitative guidance was provided, and the filing states that risk factors had no material changes from the March 31, 2026 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and EPS reported
- Reported revenue was $40.748 million and EPS was $0.01 for the period. The filing excerpt does not provide comparable prior-period or prior-year revenue, margin, or EPS figures.
- OxyContin litigation dismissed
- The company dismissed the Purdue Pharma patent-infringement case on June 12, 2026, after the parties agreed to a stipulated dismissal.
- OxyContin launch remains conditional
- Elite stated that launch of generic OxyContin depends on FDA approval and the outcome of litigation or expiration of patents listed in the Orange Book.
- Material control weaknesses identified
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing 3 categories of material control deficiencies.
- Remediation efforts underway
- The company began remediation during the 3 months ended June 30, 2026, focusing on control documentation and oversight of manufacturing, marketing, distribution, and reporting activities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness in financial controls
- Management concluded that internal control over financial reporting was not effective as of June 30, 2026. The filing cites insufficient segregation of duties, limited personnel and resources, and weaknesses in control activities and documentation, creating a reasonable possibility that a misstatement may not be prevented or detected timely.
- Remediation timing remains uncertain
- The company stated that the material weaknesses cannot be considered remediated until remedial controls operate for a sufficient period and management completes testing of their design and operating effectiveness. No remediation completion date was provided.
- FDA and patent approval uncertainty
- Although the Purdue Pharma case was dismissed on June 12, 2026, Elite’s generic OxyContin launch still depends on FDA approval and patent-related outcomes, leaving commercialization timing uncertain.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.01
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance, nor does it state that prior guidance was raised, maintained, lowered, or withdrawn.
The filing reads worse than the one before it.
What came before.
- 10-K · June 29, 2026
- Elite Pharmaceuticals demonstrated a significantly positive performance in FY 2026, with revenues increasing by 77% to $148.9 million over the previous year, driven by new product launches and a surge in manufacturing…
- 10-Q · February 17, 2026
- Elite Pharmaceuticals reported robust growth in Q3 fiscal 2026, achieving revenues of $31.6 million, a 120% increase year-over-year, though this fell short of consensus estimates. The company recorded an EPS of $0.01,…
- 10-Q · November 14, 2025
- Elite Pharmaceuticals, Inc. reported robust growth in Q2 of fiscal 2025, with revenue reaching $36.3 million, a 92% increase compared to $18.9 million in Q2 of fiscal 2024. EPS was reported at $0.01, showing a…
- 10-Q · August 14, 2025
- Elite Pharmaceuticals, Inc. reported Q4 fiscal year 2025 results showing significant growth, with revenues of $40.21 million, up 114% from the previous year, driven by an increase in manufacturing fees. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ELTP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever